| Literature DB >> 22189732 |
Renata L Pacheco1, Renata D Lobo, Maura S Oliveira, Elthon F Farina, Cleide R Santos, Silvia F Costa, Maria Clara Padoveze, Cilmara P Garcia, Priscila A Trindade, Ligia M Quitério, Evandro A Rivitti, Elsa M Mamizuka, Anna S Levin.
Abstract
OBJECTIVE: The aim of this study was to characterize Staphylococcus aureus (MRSA) carriage in a dermatology unit.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22189732 PMCID: PMC3226602 DOI: 10.1590/s1807-59322011001200012
Source DB: PubMed Journal: Clinics (Sao Paulo) ISSN: 1807-5932 Impact factor: 2.365
Figure 1The monthly distribution of patients colonized by MRSA at the time of admission, the distribution of patients who acquired MRSA in the hospital and the MRSA colonization pressure in the dermatology unit over a 6-month period.
Characteristics of MRSA-colonized patients and non-colonized patients in the dermatology unit over a 6-month period.
| n (%) | n (%) | ||
| Male sex | 28 (44%) | 37 (47%) | 0.66 |
| Age (years)-mean (SD)-median (range) | 42.8 (21.8)42 (1-84) | 38.8 (25.7)35 (0-92) | 0.33 |
| Total days of hospitalization-mean (SD)-median (range) | 24.3 (20.8)17 (2-118) | 15.4 (24.4)8.5 (1-168) | 0.02 |
| Days of hospitalization until MRSA detection-mean (SD)-median (range) | 9.5 (10.4)6 (0-49) | NANA | |
| Hospitalization within the previous 12 months-in our hospital | 30 (47%)18 (60%) | 25% (32%)15 (60%) | 0.070.21 |
| Previous use of antimicrobial drugs | 38 (59%) | 36 (46%) | 0.12 |
| Underlying diseases | |||
| Bullous diseases | 22 (34%) | 6 (8%) | <0.001 |
| Pemphigus | 15 (23%) | 3 (4%) | <0.001 |
| Other bullous | 7 (11%) | 3 (4%) | 0.10 |
| Atopy | 11 (17%) | 10 (13%) | 0.47 |
| Cancer | 5 (8%) | 9 (12%) | 0.46 |
| Erythrodermia | 8 (13%) | 6 (8%) | 0.34 |
| Infectious | 7 (11%) | 8 (10%) | 0.90 |
| Auto-immune | 4 (6%) | 8 (10%) | 0.10 |
| Psoriasis | 6 (9%) | 8 (10%) | 0.86 |
| Eczema | - | 7 (9%) | 0.14 |
| Death during hospitalization | 4 (6%) | 1 (1%) | 0.11 |
SD: standard deviation NA: not applicable.
SCCmec type and molecular type of 67 MRSA isolates according to the origin of acquisition.
| III (13) | E (9) | |
| F (2) | ||
| G (2) | ||
| IV (14) | B (6) | |
| A (5) | ||
| C (3) | ||
| ND (1) | C (1) | |
| III (4) | E (4) | |
| IV (11) | A (7) | |
| C (4) | ||
| ND (1) | C (1) |
MRSA: methicillin-resistant S. aureus; PFGE: pulsed-field gel electrophoresis; ND: not determined.
Multilocus sequence typing results for 10 methicillin-resistant S. aureus subtypes that colonized patients hospitalized in the dermatology unit over a period of 6 months.
| A1 | 1176 | IV |
| B1 | 8 | IV |
| C1 | 97 | IV |
| C6 | 5 | ND |
| D | 8 | IV |
| E1 | 239 | III |
| E8 | 239 | - |
| E9 | 239 | - |
| F | 239 | III |
| G | 239 | III |
PFGE: pulsed-field gel electrophoresis; SCCmec: staphylococcal chromosomal cassette mec; ND: not determined; -: absence of mecA.
The SCCmec and molecular types of 11 MRSA isolates obtained from healthcare workers at the beginning and the end of the study.
| IV (5) | C (3)B (1)A (1) | |
| IV (5)III (1) | A (1)B (3)C (1)E (1) |
MRSA: methicillin-resistant S. aureus; PFGE: pulsed-field gel electrophoresis.
Antimicrobial susceptibility according to SCCmec type of 71 MRSA isolates that colonized 60 patients and 11 healthcare workers in the dermatology unit over a period of 6 months.
| SCC | SCC | ||
| Chloramphenicol | 20 (80%) | 46 (100%) | 66 (93%) |
| Ciprofloxacin | 0 | 43 (93%) | 43(61%) |
| Clindamycin | 0 | 35 (76%) | 35 (49%) |
| Erythromycin | 0 | 15 (33%) | 15 (21%) |
| Gentamicin | 0 | 27 (59%) | 27(38%) |
| Rifampicin | 9 (36%) | 46 (100%) | 55 (77%) |
| Sulfamethoxazole/ trimethoprim | 0 | 45 (98%) | 45 (63%) |
| Tetracycline | 0 | 40 (87%) | 40 (56%) |
| Vancomycin | 25 (100%) | 46 (100%) | 71 (100%) |